Alcidion Group Limited · ASX:ALC
Alcidion — H1 2025 Earnings Presentation
25 slides from Alcidion's earnings presentation, Feb 27, 2025
Slide 1: H1 FY25 Results Presentation
H1 FY25 Results Presentation 27 February 2025
Slide 2: Smarter, Modular, Cloud Native
SMARTER Alcidion Group Limited (ASX: ALC) was founded with one simple belief: MODULAR Smart technology can drive meaningful change CLOUD NATIVE Alcidion is delivering smarter solutions for clinicians and enabling our clients to harness the power of their data. Alcidion’s platform, Miya Precision, de
Slide 3: About Alcidion
Alcidion is a healthcare software and informatics company providing an About Alcidion innovative technology platform to improve the efficiency and quality of patient care ASX listed health informatics company 36 Health Systems Exclusive focus on healthcare technology 108 Hospitals 100+ clinical syst
Slide 4: H1 FY25 Highlights
H1 FY25 Highlights
Slide 5: H1 FY25 – Executive Summary
H1 FY25 – Executive Summary $17.6M $18.3M $61.3M $39.5M $0.5M H1 FY25 revenue H1 New TCV2 sales FY25 YTD New TCV FY25 contracted revenue Underlying EBITDA sales Includes Down 7% on pcp1,as Includes both Highest new TCV contribution from Material expected due to contracted & signed in Company’s Hywel
Slide 6: H1 FY25 – Executive Summary (cont.)
H1 FY25 – Executive Summary (cont.) • Peninsula Health (AUS): Miya Precision deployment; TCV of $3.7M over 5 years • North Adelaide Local Health Network (AUS): Miya Precision & mobile clinical comms solutions; $4.5M TCV over 5 years New • Hume Rural Health Alliance (AUS): Miya Precision as an enterp
Slide 7: H1 FY25 Financials
H1 FY25 Financials
Slide 8: Profit & Loss
Profit & Loss Annually recurring product revenue expected to increase in future periods as benefits of contracts signed in H1 are recognised, underpinning confidence in future profitability Profit & loss (A$000) H1'24 H1'25 % change Recurring 1• Revenue of $17.6m, down 7% on pcp, driven by lower pro
Slide 9: Revenue Dashboard
Revenue Dashboard 40.4 37.1 34.4 21.4 18.0 21.5 25.9 H1 vs H2 14.8 43% 17.6 Geographical Revenue Split $17.6M 19.0 19.1 17.6 Split (%) ($M) Total 57% 12.9 11.1 UK FY21 FY22 FY23 FY24 H1'25 ANZ H1 H2 40.4 37.1 57% 41% 39% 29% 22% 34.4 10.0 7.5 6.2 78% 25.9 2.3 2.2 71% 4.9 3.4 Revenue 5.6 3.1 24.7 26.
Slide 10: Balance Sheet
Balance Sheet Balance sheet ($000) 30-Jun-24 31-Dec-24 Cash & cash equivalents 1 11,798 7,681 1• $7.7m cash and no debt as of 31 December 2024 Trade & other receivables 2 5,214 9,759 Other assets 1,527 1,645 2• Trade receivables increased over prior year, underpinning historically Current assets 18,
Slide 11: Cashflow
Cashflow Cash flow ($000) 1H'24 1H'25 Receipts from customers 15,105 15,342 1• H1 FY25 operating cash flows improved $7.3M; primarily driven by Payments to suppliers & employees (26,505) (19,481) material reduction and realignment of cost base in Q3’24 Income tax paid - - Interest received 30 57 – P
Slide 12: H1 FY25 Operations
H1 FY25 Operations
Slide 13: Notable Contract Wins & Renewals
Notable Contract Wins & Renewals New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity Hume Rural Health Alliance (AUS) Hywel Dda (Wales) • TCV of $4.0m over 5 years • TCV of $5.5M over 5 years (with 2-year option • Miya Precision deployed as
Slide 14: EPR Validation: North Cumbria
EPR Validation: North Cumbria Signed contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC) for new EPR platform solution Contract Signed - Overview Key Contract Terms • Selected following a competitive tender process 10 years Contract duration • Deploy Miya Precision encompassing f
Slide 15: Successful Deployments in H1 FY25
Successful Deployments in H1 FY25 Product Implementation and technical services have always been a strength of the Alcidion business Hume Rural Health Alliance (AUS) Hampshire Hospitals NHS Foundation Trust • First site went ‘live’ in late Oct-24 • First deployment of Miya Emergency across three hos
Slide 16: Market Position & Opportunity
Market Position & Opportunity
Slide 17: Competitive Advantage
Competitive Advantage Competitors The Miya Precision Platform • Specialised solutions without a platform approach ✓ Industry leading modular data interoperability platform • Limited point to point integration at high cost ✓ Independently proven to deliver released capacity Clinically Intuitive Inter
Slide 18: The Modular Miya Precision Platform
The Modular Miya Precision Platform Real Time Analytics Hospital at a Glance Predictive Analytics Patient Logistics Mgmt Outlier Resolution network icon graph icon resolve icon real time analytics eye icon hospital icon icon Miya Command Capacity Management Extensible Data Set Discharge Barriers Hot
Slide 19: The Opportunity in Australia
The Opportunity in Australia The Australian market continues to present opportunities to grow the footprint of Alcidion and Miya Precision. South Australia Queensland SA LHNs are keenly The Director observing the General has been NALHN rollout and given a mandate to evaluating Miya resolve QLD patie
Slide 20: Opportunities with the NHS
Opportunities with the NHS The NHS is continuing to roll out funds from the EPR program, and we expect Flow to be a significant priority in the soon to be released NHS 10-year plan. England Scotland NHS funding for ICS’s Scotland continues to manage flow to be a growth represents continued market ad
Slide 21: Outlook
Outlook
Slide 22: Outlook
Outlook FY25 contracted revenue signed to date will result in full year revenue growth (vs. FY24) and positive EBITDA and cashlfow • FY25 contracted revenue stands at $39.5M (includes Hywel Dda and North Cumbria) • Confident of delivering a positive EBITDA and cashflow result for the full year FY25
Slide 23: Investment Highlights
Investment Highlights • Large Addressable Market Strong Financial Profile Marquee Customers • 146 Acute UK NHS Trusts; ALC with foothold • $39.5M current contracted & renewal • $37.5M over 10 years with North Cumbria in only ~27% revenue to be recognised in FY25 for Miya Precision suite to provide n
Slide 24: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continu
Slide 25: Slide 25